Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporation's xMAP

   Natural Molecular Testing Corporation Launches an Expanded Personalized
        Medicine Panel Built on Luminex Corporation's xMAP Technology

Partnership Advances Pharmacogenomics for Improved Patient Care

PR Newswire

SEATTLE, June 11, 2013

SEATTLE, June 11, 2013 /PRNewswire/ --Natural Molecular Testing Corporation
(Natural Molecular, NMTC), a privately-owned company providing groundbreaking
clinical diagnostic molecular testing and services in the medical genomics
field, announced today the launch of their laboratory developed comprehensive
Personalized Medicine Panel. This cardiac panel, commercialized by Natural
Molecular, is comprised of 42 targets and built using Luminex Corporation's
(NASDAQ: LMNX) xMAP® Technology.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

"Our goal is to bring the latest advancements in medical science and
technology to help clinicians do one simple thing: provide the best possible
care for their patients," said Beau R. Fessenden, CEO of Natural Molecular.
"By converting to Luminex's xMAP technology, we can improve our throughput and
workflow efficiency with more comprehensive and highly sensitive assays that
set us apart in the marketplace. The flexibility and high throughput of the
Luminex platform combined with the ability to add additional biomarkers make
the technology unique and best suited to our expanding needs."

Each year more than 2 million Americans are hospitalized due to adverse drug
reactions which lead to an estimated 100,000 deaths.^1 Molecular testing
allows physicians to diagnose genetic abnormalities in patients, providing
guidance in selecting optimal medications and doses of medications while
minimizing risk for a wide variety of common conditions such as chronic heart
disease and pain.

"We are excited to be expanding our relationship with Natural Molecular in the
important area of pharmacogenomics," said Patrick Balthrop, president and CEO
of Luminex. "It is valuable for a physician to know whether a specific
therapeutic compound will be most beneficial for a particular patient. Through
the use of genetic testing, driven by the throughput and scalability of our
technology and the unique services of NMTC, our two companies are working
together to optimize patient outcomes and lower overall health-care costs. We
look forward to expanding opportunities with Natural Molecular, a leader in
pharmacogenomic testing."

The financial terms of the multi-year collaboration and license agreement were
not disclosed.

About Personalized Medicine Panel
Natural Molecular's new comprehensive Personalized Medicine Panel features a
simple laboratory workflow based on Luminex's flexible xMAP Technology.
Multiplexing a comprehensive set of biomarkers together from a single sample
offers significant improvements in testing efficiency saving valuable time and
increasing throughput. The panel includes the following:

CYP450 2C19
CYP450 2C9
CYP450 2D6
CYP450 3A4
CYP450 3A5
ABCB1
VKORC1
MTHFR
Factor II
Factor V Leiden

About Natural Molecular Testing Corporation

Natural Molecular Testing Corporation (NMTC) is a privately-owned,
high-complexity molecular testing facility. NMTC provides comprehensive
genetic testing solutions that improve patient care through the latest
breakthroughs in genomic technology.

For more information about Natural Molecular Testing Corp., visit
www.naturalmolecular.com

About Luminex Corporation (NASDAQ: LMNX)

Luminex is committed to applying its passion for innovation toward advancing
healthcare and research worldwide. The company is transforming global
healthcare and life-science research through the development, manufacturing
and marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte platform, MultiCode® real-time polymerase
chain reaction (PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and researchers. Luminex's
technology is commercially available worldwide and in use in leading clinical
laboratories, as well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. Luminex is meeting the needs of customers in markets
as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical
research including genomic and proteomic research, personalized medicine,
biodefense research and food safety. For further information on Luminex
Corporation and the latest advances in multiplexing using award winning
technology, please visit http://www.luminexcorp.com/.

References:

1."Cytochrome P450 Enzyme Genotyping: Optimizing Patient Care Through
    Pharmacogenetics."Communique30.9 (2005): Mayo Medical Laboratories.
    http://www.mayomedicallaboratories.com/

Natural Molecular Contact:

Media:
Ken Wallace
Natural Molecular Testing Corp
Director of Business Development
1-888-442-8881

Luminex Contact:

Investors:
Matt Scalo
Luminex Corporation
mscalo@luminexcorp.com
512.336.3587

Media:
Mimi Torrington
Luminex Corporation
mtorrington@luminexcorp.com
512.219.8020

SOURCE Natural Molecular Testing Corporation; Luminex Corporation

Website: http://www.luminexcorp.com